NCF2/p67phox, the activating subunit of NADPH oxidase, is aberrantly expressed in several genitourinary tumors with clinical significance, including ccRCC [23, 53–55], prostate cancer [56], urothelial carcinoma [20] and testicular cancer [57]. Here, FMO5 is linked to testicular cancer.